SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Hemispherx Biopharma, Inc. on June 20, 2016, regarding an event that occurred on June 16, 2016. The registrant is a Delaware corporation headquartered in Philadelphia, PA. Note: The input metadata references "AIM Immunotech Inc.", but the filing text explicitly identifies the registrant as "Hemispherx Biopharma, Inc."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements.
Material Changes
The material change reported is the resignation of Iraj Kiani as a member of the Board of Directors, effective June 16, 2016.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the director departure.
Key Facts for Investor Verification
- Confirm the effective date of Iraj Kiani's resignation from the Board of Directors (June 16, 2016).
- Verify if a replacement director has been appointed or if the board seat remains vacant.
- Check subsequent filings for any financial impact or strategic shifts resulting from this governance change.